Revolution Medicines, Inc.

NASDAQ:RVMD

Biotechnology

Healthcare
$159.82 +2.28%

+$3.60 today

Market cap
$34.57B
Beta
1.41
P/E (TTM)
-23.3
EPS (TTM)
-$6.92
52W Low $34.00High $166.50

Volume 2.34M

Average 3.10M

RVMD Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Revolution Medicines, Inc.NASDAQ: RVMD

Accounts Payables · Q2 FY2026 · quarter ended Jun 2026

Accounts payables dips below year-ago levels

Q2 FY2026 accounts payables of $5.03M fell 42.6% year over year, behind the +14.3% change in trailing-twelve-month accounts payables. Sequentially, it fell 70.2% from the prior quarter. Over 3 fiscal years it compounded at +9.4% a year.

Context

  • Accounts payables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -42.6% toward the trailing-twelve-month pace of +14.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$5.03M-70.2% QoQ
Last fiscal yearDec 2025
$9.54M+247.5% YoY
LTMJun 2026
$30.93M+14.3% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-42.6%——
1 year+247.5%——
3-year CAGR+9.4%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
9.54M USD
Year-over-year change
+247.5%
4-year CAGR
+43.7%

Accounts Payables vs competitors

How RVMD compares with its peers on the latest reported figures

  • RVMD's LTM Jun 2026 accounts payables of $30.93M is the largest of the 11 companies compared; the peer median is $1.1M.
  • Its year-over-year change of +14.3% is the 7th highest of 11, against a peer median of +32.2%.
  • Over three fiscal years its annual growth of +9.4% compares with a peer median of +25.7%.
RVMD Competitors Peer median
Accounts Payables for RVMD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RVMDRevolution Medicines, Inc.LTM Jun 2026$30.93M +14.3%+9.4%—
NRIXNurix Therapeutics, Inc.LTM Aug 2026$25.05M +537.3%—3.6%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$7.04M -374.8%—68.0%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$3.02M -73.7%+13.1%1.3%
VSTMVerastem, Inc.LTM Mar 2026$2.4M +1061.2%+48.0%4.8%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$1.54M +244.4%+164.1%3.6%
ELVNEnliven Therapeutics, Inc.LTM Sep 2026$1.4M +348.4%+25.7%—
ERASErasca, Inc.LTM Sep 2026$798K +27.9%-8.8%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$448K +36.6%+70.0%—
TNGXTango Therapeutics, Inc.LTM Sep 2026$365K -82.6%——
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$341K -76.2%+15.4%—
Peer median (excluding RVMD) $1.1M+32.2%+25.7%3.6%

Competitors are the stored peer set for RVMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(187.09M)(248.71M)(436.37M)(600.09M)(1.13B)
Depreciation & Amortization7.33M9.66M9.31M11.82M16.56M
Deferred Income Tax0(419K)(3.91M)(762K)0
Stock-Based Compensation20.72M31.2M61.77M79.2M118.39M
Change in Working Capital8.72M(13.49M)40.66M1.17M86.82M
Accounts Receivables464K1.26M3.42M1.25M0
Inventory7.68M0000
Accounts Payables2.24M7.29M32.47M(6.47M)9.54M
Other Working Capital(1.66M)(22.03M)4.77M6.38M77.29M
Other Non-Cash Items3.13M(2.64M)(22.04M)(48.77M)11.79M
Operating Cash Flow(147.18M)(224.4M)(350.57M)(557.44M)(897.74M)
Capital Expenditures(6.53M)(10.82M)(7.73M)(10.31M)(15.99M)
Acquisitions (Net)135.59M13.3M000
Purchases of Investments(671.34M)(612.77M)(1.06B)(2.14B)(1.79B)
Sales of Investments535.75M599.47M724.05M1.59B1.93B
Other Investing Activities(135.59M)(13.3M)000
Investing Cash Flow(142.12M)(24.12M)(342.6M)(554.39M)118.06M
Debt Repayment0000244.22M
Common Stock Issued291.24M298.05M392.39M959.13M377.09M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.94M3.39M836.81M284K220K
Financing Cash Flow294.18M301.43M1.23B959.41M621.52M
Effect of Forex Changes00(1.29M)(667K)0
Net Change in Cash4.88M52.92M534.74M(153.08M)(158.16M)
Free Cash Flow(153.71M)(235.22M)(358.3M)(567.74M)(913.73M)

Revolution Medicines, Inc.

NASDAQ:RVMD

Intrinsic Alpha fair value

Locked

Current Price

$159.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.